<?xml version="1.0" encoding="UTF-8"?>
<ref id="bb0060">
 <label>12</label>
 <element-citation publication-type="journal" id="rf0060">
  <person-group person-group-type="author">
   <name>
    <surname>Chen</surname>
    <given-names>C.N.</given-names>
   </name>
   <name>
    <surname>Lin</surname>
    <given-names>C.P.</given-names>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>K.K.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>W.C.</given-names>
   </name>
   <name>
    <surname>Hsieh</surname>
    <given-names>H.P.</given-names>
   </name>
   <name>
    <surname>Liang</surname>
    <given-names>P.H.</given-names>
   </name>
   <name>
    <surname>Hsu</surname>
    <given-names>J.T.</given-names>
   </name>
  </person-group>
  <article-title>Inhibition of SARS-CoV 3C-like protease activity by Theaflavin-3,3â€²-digallate (TF3)</article-title>
  <source>Evid. Based Complement. Altern. Med.</source>
  <volume>2</volume>
  <year>2005</year>
  <fpage>209</fpage>
  <lpage>215</lpage>
 </element-citation>
</ref>
